Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...

LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...

Jefferies downgraded Cargo Therapeutics (CRGX) to Hold from Buy with a price target of $3, down from $32. The company announced the “surprising and disappointing news” that it will discontinue ...

Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq ... and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

BOSTON, Jan. 27, 2025 /PRNewswire/ -- Averna Therapeutics, Inc. ("Averna"; formerly known as Exsilio Therapeutics, Inc.), a biotechnology company developing genomic medicines that insert ...

logo will not comply with upcoming new requirements ... leading many municipalities and brands to no longer use it. “Ensuring accessibility is about equity and inclusion,” Gauvin said.

ROCKVILLE, MD—June Almenoff, a director at Avalo Therapeutics, Inc. (NASDAQ:AVTX), has purchased a total of 1,000 shares of the company's common stock, according to a recent ...